WHO recommends dolutegravir as preferred HIV treatment option

30 July 2019

Article: 53/3004

The World Health Organization (WHO) has recommended the use of the HIV drug dolutegravir (DTG) as the preferred first- and second-line treatment for all populations, including pregnant women and those of childbearing age. The recommendation, made on 22 July 2019, is based on new data from two large clinical trials comparing the efficacy and safety of DTG and efavirenz (EFV) in Africa that have now expanded the evidence base.

DTG is a drug that is more effective, easier to take, and has fewer side effects than alternative drugs which are currently used. DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens.

Source: WHO, 22 July 2019